

Index

- Aboy, M. 261
access payments, and open bioresources
 249, 250–51
Ahmad-Nejad, P. 222
Albert, M. 6–7
Allen, C. 175
Allen, N. 191
Almeling, R. 182
Anderson, W. 5, 14
Andreoli-Versbach, P. 209
Andrews, L. 59
Andries, P. 201
Annas, G. 161
Aplin, T. 249
Appelbaum, P. 14, 161
Arzberger, P. 3
Asslaber, M. 230
Asveld, L. 190–91
Atkinson-Grosjean, J. 131
Auflage, C. 112
Australia 121–2, 126
Austria 220, 221, 226, 227
autonomy protection 4–5, 8, 13, 17,
 36–7, 79–80, 88, 128, 134
 see also confidentiality;
 informed consent; privacy
 concerns
Azoulay, P. 207

Bachmann, R. 132
Ballantyne, A. 160
Barnes, R. 59
Barry, A. 239
Baumbusch, J. 198

Bekelman, J. 193–4
Belluz, J. 183
Benesova, L. 220
Benkard, G. 112
Bentwich, M. 188
Bernitz, U. 112–13
Betsou, F. 234
Beyleveld, D. 93, 94, 100
Bhandari, M. 194
Biobrick Public Agreement, open
 bioresources 249
biohazards, and health and safety 69–70
biohoarding (low usage) concerns 123
biomarker identification 47–8, 58, 157,
 222–3, 229, 230, 231, 241
biopiracy claims 5
Birch, K. 210
Björk, B.-C. 246
Bjugn, R 5
Blakemore, E. 178
Blasimme, A. 4
Blok, V. 190
Boddington, P. 120, 122
Boggio, A. 28, 35
Bolivia 160
Borgman, C. 26, 36
Borry, P. 37, 258, 259
Bosk, C. 9
Bossow, T. 56–71
Botti, G. 46, 47, 50, 184
Bovis, C. 88
Boyer, G. 53, 216
Broekstra, R. 135, 151

- Brownsword, R. 93, 100, 106, 107, 108, 243
- Bruinenberg, M. 238
- Bubela, T. 189
- Budimir, D. 196
- Budin-Ljøsne, I. 124, 151
- Burk, D. 54
- Burke, W. 179
- Burstein, P. 180
- Cadigan, R. 5, 53, 197
- Caixeiro, N. 222
- Cambon-Thomsen, A. 158, 255
- Cambrosio, A. 3
- Campbell, A. 130
- Canada 182
- Caplan, A. 158, 159
- Capocasa, M. 258
- Capron, A. 210, 258, 259
- Carter, A. 234
- Caso, R. 147
- Catchpoole, D. 123
- Caulfield, T. 67, 68, 107, 131, 132, 146–9*passim*, 173–84, 189, 190, 192, 193, 196, 197, 198, 203, 207, 253–4
- Chadwick, R. 255
- Chalmers, D. 146, 243, 260
- Chambliss, D. 9
- Chandrasekharan, S. 207
- Chapman, A. 74
- Charo, R. 175
- Chesbrough, H. 201, 204, 207, 246
- Christakis, N. 161
- Clark, B. 56–71
- Clarke, L. 88
- Clarysse, B. 212
- Claude, R. 74–5
- Clemence, M. 196, 197
- Coathup, V. 125
- collaboration
- international *see* international collaboration in genetic research
- responsible research and innovation (RRI) 189–90, 194–5, 199–200, 201, 206–8 and sharing of samples, Dynamic Consent concept 120, 128–9 *see also* harmonization approach; networks
- Colledge, F. 3, 217
- Collins, F. 49, 190
- commercialization
- and consent problem 180–81
- Dynamic Consent concept 122–3, 131–2, 137–8, 148–9
- industry involvement concerns 194, 198–200
- innovation infrastructure for translational medicine 53–4
- responsible research and innovation (RRI) 193–203, 196–7, 208, 209–11, 212–14
- scientific productions and human rights 79
- commons framework *see* knowledge institutions, knowledge commons research framework
- computable consent, Dynamic Consent concept 135
- confidentiality 16, 182–3, 248–9, 252–3 *see also* autonomy protection; privacy concerns
- conflicts of interest 15–16, 190–91, 193
- consent
- developing countries *see* developing countries, exploitation and vulnerabilities in consent to biobank research

- dynamic *see* Dynamic Consent headings
- informed *see* informed consent approach
- processes and standards, human biosamples in bioscience industries 67–8
- sample collection *see* sample collection
- withdrawal rights 75–7, 143, 151, 197
- consent problem 173–84
- broad consent approach 177
 - confidentiality risks 182–3
 - data breaches 181–2
 - free and informed consent 181
 - funding issues and commercialization 181
 - genetic information concerns 179–80, 182–3
 - HeLa cell line controversy 178
 - legal uncertainty 175–6
 - media hype concern 178–9, 183
 - perceived rights of control 178–80
 - privacy and discrimination concerns 121, 128, 181–3
 - public perception 177–84
 - public trust and commercialization 180–81
 - public-private partnerships 180–81
 - technology opportunities 183–4
- Contreras, J. 35
- Cook-Deegan, R. 52, 54, 207, 244
- Cooper, M. 5
- Council for International Organizations of Medical Sciences' (CIOMS) 163–4
- Cranley, E. 54, 178
- Crespo, M. 189–90
- Critchley, C. 57, 130, 180, 192, 194, 196, 197, 198, 211, 213
- Cunningham, H. 5
- Cunningham, J. 178
- Curtis, J. 49
- D'Abramo, F. 181
- Daley, B. 54, 178, 179
- Dasgupta, P. 246
- data breaches 181–2
see also privacy concerns
- data fragmentation challenge 44–5, 53–4
- data sharing 4–5, 125
- EU BBMRI network, MIABIS (Minimum Information About Biobank Data Sharing) 51, 235, 239
 - see also* open access; privacy issues
- David, P. 246
- Davies, S. 191
- De Souza, Y *ix*
- De Vries, J. 121
- De Vries, R. 177, 180
- Debackere, K. 201
- deferential vulnerability, developing countries 165–6, 168, 169–70
- Denmark 11, 16, 96–7, 98, 104, 109–10, 231
- developing countries, exploitation and vulnerabilities in consent to biobank research 156–72
- biomarker identification 157
 - education and poverty levels effects 161
 - exploitation of research subjects 159–62
 - harmonization of guidelines 158–9, 171–2
 - informed consent issues and future projects 158–9

- international research potential 157
- invalid consent account 161–2, 163
- legislation fragmentation 159
- medical research exploitation 160–62
- developing countries, exploitation and vulnerabilities in consent to
 - biobank research, exploitation with consent and benefits 162–6
 - deferential vulnerability 165–6, 168, 169–70
 - juridic vulnerability 165–6, 169
 - layered approach to vulnerability 164–5
 - vulnerability to exploitation, understanding and labelling 163–4
- developing countries, exploitation and vulnerabilities in consent to
 - biobank research, Pakistan case study, blood samples 166–70
 - medical profession association as participant motivation 168, 169–70
 - participation motivation 167–8
 - vulnerabilities 168–70, 171–2
- Dierickx, K. 37
- digital technologies, Dynamic Consent concept 118–20
- discrimination issues 78, 181–3
- disease-based biobanks 232
- Doerr, A. 184
- Douglas, C. 46, 132
- Douglas, S. 115
- Dove, E. 3, 207, 244
- Drake, A. 57
- Dressler, L. 77–8
- Dridi, H. 189–90
- drug development 47, 57–8, 180, 191–2, 202, 247
- Ducato, R. 147
- Dynamic Consent concept and
 - sustainability 117–29
 - biobank usage and sustainability 122–3
 - biohoarding (low usage) concerns 123
 - clinical care integration possibilities 127–8
 - collection of participants' self-reported health and lifestyle data 124–5
 - digital technologies 118–20
 - Dynamic Consent definition 124–6
 - EnCoRE (Ensuring Consent and Revocation) project 128
 - ethical and legal standards 126–7
 - family members, inclusion of 119, 126, 127
 - global biobanking market value 122–3
 - informed consent approach 118–19
 - international collaborations and sharing of samples 120, 128–9
 - legal framework 120–22
 - participant autonomy and real and effective choice 128, 134
 - regulation fragmentation 120–22, 126
 - translational research systems, biobank involvement in 123
 - unforeseen studies, dealing with, and broad consent solution issues 119–21, 124–5, 126–8
- Dynamic Consent concept and
 - sustainability, trust challenges 130–55

- commercialization challenges and translational research 131–2, 137–8, 148–9
- computable consent 135
- consultation and communication with communities and interest groups 145
- Dynamic Consent as tool for generating trust 151–4
- electronic consent 135, 151–2
- encryption of sensitive data 151
- funding issues 146, 148
- future research opportunities 134, 153–4
- governance mechanisms and consent procedures 145, 146–7, 153
- information evaluation and transparency 143–4, 149, 152–4
- informed consent principle 133–5, 142
- ownership, access and use 146–9
- participants and interpersonal support 138, 151–3
- participation withdrawal rights 143, 151
- transnational collaborations 148–9
- trust challenges 139–50
- trust concept 132–3, 136
- trust levels 137–8, 141–2, 146–8
- trust and trustworthiness distinction 136–7
- uncertainty and risk factors 136–7
- education and poverty level effects, developing countries 161
- Edwards, T. 174
- Egan, J. 202
- Eilers, L. 22
- Einsiedel, E. 211
- Eiseman, E. 218
- Eisenberg, R. 44, 45, 49, 50, 54, 188
- electronic consent, Dynamic Consent concept 135, 151–2
- Elger, B. 158, 159
- Emanuel, E. 160
- EnCoRE (Ensuring Consent and Revocation) project 128
- Estonia 238–9
- ethical concerns 9–11, 62–4, 65, 126–7, 193, 196–7, 236
see also morality concerns
- EU
- BBMRI network, MIABIS (Minimum Information About BIobank Data Sharing) 51, 235, 239
- BBMRI-ERIC infrastructure *see* networks, EU BBMRI-ERIC infrastructure
- Brüstle v Greenpeace* 95, 99, 111
- Casa Fleischhandels-GmbH v Bundesanstalt für landwirtschaftliche Marktordnung* 94
- Deutsches Milch-Kontor GmbH v Hauptzollamt Hamburg-Jonas* 94
- General Data Protection Regulation 120–21
- GenomeEUtwin project 237
- Horizon2020 148, 190, 203
- International Stem Cell Corporation v Comptroller General of Patents, Designs and Trade Marks* 95
- Karen Millen Fashions Ltd v Dunnes Stores* 94

- Netherlands v Parliament and Council* [2001] 94, 98, 105, 111
- Oviedo Convention on Human Rights and Biomedicine 75, 77–8, 79, 102–3, 104, 105, 107–8
- responsible research and innovation (RRI) *see* responsible research and innovation (RRI)
- European Charter for Access to Research Infrastructures 217
- European Court of Human Rights
- Anheuser-Busch v Portugal* 80–81
- Costa and Pavan v Italy* 104
- Evans v the United Kingdom* 104
- European patent law, free and informed consent in 92–116
- Biotech Directive 93–7, 98–101, 111–16, 181
- Charter of Fundamental Rights of the European Union 105–6
- ethical and moral principles and nonpatentability 99–101
- European Convention on Human Rights (ECHR) 102–3, 104
- European Patent Convention (EPC) 95, 96
- health law 108–10
- human biological material (HBM) 92, 93, 95, 97, 100, 101, 103, 107–8, 114–15
- human embryonic stem cells 95, 99
- large-scale population projects and donors' consent issues 108–9
- morality exclusion 95, 98, 100, 111, 112–16
- patentability and balancing of interests 114–16
- regulatory rule argument 98–9, 101, 111, 116
- residual tissue use 108
- European patent law, free and informed consent in, fundamental rights 99, 100–108, 111–13
- persons participating in research projects 103
- right to human dignity and integrity 103, 104–8
- right to make autonomous decisions 107
- right to private life 102–3
- European Patent Office (EPO) 99–101, 111–12
- Breast and ovarian cancer/ UNIVERSITY OF UTAH* 101
- Euthanasia compositions/ MICHIGAN STATE UNIV.* 114
- Howard Florey/Relaxin* 100, 111
- LELAND STANFORD/Modified Animal* 101, 111
- Plant cells/PLANT GENETIC SYSTEMS* 100
- Evans, B. 3, 28, 34–5, 51
- Evans, D. 139
- Evans, J. 179
- Evers, K. 192, 193, 198, 210
- expiration date for biobanks 216–28
- biomarkers 222–3
- collection strategies 219–21
- collections with predefined expiry dates 220
- data availability effects 223
- data explosion vs useful information 224–5

- expiration date definition
 219–25
 informed consent expiry date
 218
 open-ended diagnostic sample
 collections 220–21
 planned application effects
 223–4
 research infrastructure and
 access policies 217–18
 sample quality issues 220–23,
 225–6
 sample sharing barriers 217
 storage conditions and duration
 and sample types 220–23,
 225–6
 termination costs 218–19, 227
 value analysis vs biospecimen
 costs 225–6
 see also quality standards
 exploitation, developing countries *see*
 developing countries, exploitation
 and vulnerabilities in consent to
 biobank research
 Eyal, N. 142, 158

 FAIR Guiding Principles for data
 management 50
 family members, inclusion of, Dynamic
 Consent concept 119, 126, 127
 Fanni, S. 104
 Ferrari, M. 145
 Finland 13, 16, 232
 Fobelets, G. 76, 78
 Ford, R. 52, 53
 Forrow, S. 50
 Foster, M. 253
 Frank, L. 231
 free and informed consent, EU *see*
 European patent law, free and
 informed consent in
 Freedman, L. 229

 Friedewald, M. 174, 175
 Friedman, J. 201, 204
 Friese, C. 20
 Friesike, S. 204
 Frischmann, B. 28, 29, 48, 50, 51, 52
 funding issues 51–2, 146, 148, 181,
 197–8, 212, 238
 future research 134, 153–4, 263

 Gadarian, S. 182
 Galli, J. 238
 Gallini, N. 200
 Gambetta, D. 137
 Gandomi, A. 224
 Gbadegesin, S. 160
 Gee, S. 243, 250, 258
 Geissler, P. 9, 16
 genetic information concerns 18, 179–80,
 182–3, 233
 genetic research collaboration *see*
 international collaboration in
 genetic research
 Gervais, D. 84
 Ghafele, R. 207
 Gibbons, S. 249, 255
 Gibson, S. 258, 259
 Giddens, A. 137
 Giesbertz, N. 183
 Gikonyo, C. 170
 Gitter, D. 147, 248, 253
 Global Alliance for Genomics and Health
 188–9
 Gold, R. 147, 214, 243, 247–8, 251, 253,
 258, 259
 Gorges, T. 48
 Gostin, L. 176
 Gottweis, H. 37, 73, 76, 157, 193
 governance structure
 and consent procedures,
 Dynamic Consent concept
 and trust challenges 145,
 146–7, 153

- and knowledge institutions
 - 26–7, 28–31, 32–3, 34–7
 - networks 239–40
 - and supply chains 58–61, 61,
 - 62–4, 68–9
 - see also* legal framework
- Grabowski, H. 205
- Grady, C. 161, 163
- Greely, H. 37, 176, 179, 183
- Greenbaum, D. 147
- Griffin, M. 73
- Grodin, M. 161
- Guédon, J.-C. 246

- Haddow, G. 132, 210
- Haga, S. 182–3
- Hainaut, P. 57
- Haines, A. 198
- Hall, B. 200
- Hallinan, D. 174, 175
- Hansson, M. 131, 134, 142, 147
- Hapgood, R. 127
- Hardin, R. 136
- Harhoff, D. 200
- Harmon, S. 252
- harmonization approach 158–9, 171–2,
 - 254–7
 - see also* collaboration; networks
- Harris, J. 132, 216
- Hawkins, A. 130
- Hawkins, J. 160
- Hayden, C. 5
- health law, and European patent law
 - 108–10
- health and safety, and biohazards 69–70
- Heaney, C. 192
- HeLa cell line controversy 178
- Heller, M. 188
- Hellstadius, Å. 92–116
- Henderson, G. 24, 173, 197
- Henderson, M. 237
- Herder, M. 188
- Hermeren, G. 193
- Herrmann, J. 104
- Hewitt, R. 58, 59, 230
- Highsmith, J. 122
- Hochschild, A. 20
- Hodge, J. 176
- Hoeyer, K. 2–21, 159, 194, 196, 234
- Hoffman, S. 43, 44
- Hoffmann, B. 134
- Hogle, L. 234
- Holm, S. 134
- Holmes, A. 58
- Holtmans, S. 152
- Holtz, C. 112, 113
- Holub, P. 233
- Hong, S. 222
- Hörig, H. 148
- Horst, M. 191
- Hubel, A. 223
- Hughes, J. 83
- human biosamples in bioscience
 - industries, responsible use of
 - 56–71
 - biobanks, and downstream
 - responsible use of biosamples
 - 59–61
 - biohazard considerations 69–70
 - biomarkers of health and disease
 - 58
 - consent processes and standards
 - 67–8
 - ethical, societal, and legal status
 - 62–4, 65
 - and European patent law 92, 93,
 - 95, 97, 100, 101, 103, 107–8,
 - 114–15
 - governance requirements and
 - supply chains 58–61, 62–4,
 - 68–9
 - health and safety 69–70
 - individuals, donations from 58

- intermediaries between donors and companies 58–9
- international conventions and guidelines, monitoring developments in 65–6
- legitimacy requirement for use of biosamples 68–9, 70
- new drugs, development and testing of 57–8
- organizational management 64–5, 66, 67, 69–70
- quality requirements 69, 70
- storage control 69
- use categories 57–8
- see also* responsible research and innovation (RRI)
- human embryonic stem cells, European patent law 95, 99
- Human Genome Organization 193
- human rights *see* scientific productions and human rights
- Hunt, P. 87
- Hurst, S. 163, 171
- industry involvement concerns 194, 198–200
- see also* commercialization
- information
 - biobanks as repository for 47
 - data explosion vs useful information 224–5
 - evaluation and transparency 143–4, 149, 152–4
 - right to information and donor's right not to be informed 77–8
 - see also* knowledge institutions
- informed consent approach
 - developing countries 158–9
 - Dynamic Consent concept 118–19, 133–5, 142
 - and expiration date for biobanks 218
 - and patent law, EU *see* European patent law, free and informed consent in scientific productions and human rights 75–7
 - see also* autonomy protection; consent headings
- Ingber, D. 58
- innovation infrastructure for translational medicine 42–55
 - big data in medicine 43–7
 - biobanks as repository for information 47
 - biomarker identification 47–8
 - data fragmentation challenge 44–5, 53–4
 - health care data and research data availability 46
 - patients' retroactive involvement in trials 48
 - translational medicine development 47–8
 - unplanned analyses, potential for 46–7
 - see also* responsible research and innovation (RRI)
- innovation infrastructure for translational medicine, biobanks as data infrastructure 48–54
 - balancing data accessibility against privacy 52–3, 54
 - data fragmentation issues 53–4
 - FAIR Guiding Principles for data management 50
 - for-profit biobanks and competitiveness 53–4
 - intangible infrastructural resources 49
 - interoperability and resource and data sharing 50–51
 - nonprofit biobanks and incentives 54

- researcher access funding 51–2
 - resources for future innovation 49–50
 - sample repositories 48–9
- Institutional Analysis and Development (IAD) framework 30–31, 33
- integration possibilities, and clinical care 127–8
- intellectual property
 - and human rights *see*
 - biobanking, scientific
 - productions and human rights
 - knowledge commons research framework 31–2
 - open access/open science issues 206–9
 - patent rights in international research collaborations 189–90, 200, 201, 206–8
 - see also* patents
- intellectual property policies for large
 - bioresources 242–63
 - future direction 257–62
 - future research 263
 - harmonization and consistency approach 254–7
 - Structural Genomics Consortium (SGC) 247
 - subsectors of bioresources
 - industry 259–60
 - synthetic biology (SB) and genomics (Gx) 244, 249
- intellectual property policies for large
 - bioresources, open bioresources, fictional commitment to 244–54
 - access payments 249, 250–51
 - Biobrick Public Agreement 249
 - controlled eligibility policies 249
 - open source and open access contrast 247–8
 - openness and closedness mixed policy 250, 251–2, 253
 - openness concept and typology 244–8
 - restricted access databases 253
 - third party property rights 252
 - trade secrets or confidential information 248–9, 252–3
- International Breakpoint Mapping Consortium (IBMC) 3, 4, 6, 7–8, 10, 11–16
- International Charter of Principles for Sharing Bio-specimens and Data 255–6
- international collaboration in genetic research 2–21
 - autonomy and privacy protection 4–5, 8, 13, 17
 - biopiracy claims 5
 - conflicts of interest 15–16
 - data protection 8, 11–12
 - ethics work and infrastructural flows as analytical objects 9–11
 - flows concept 11–15
 - genetic information concerns 18, 179–80, 182–3
 - International Breakpoint Mapping Consortium (IBMC), and chromosomal rearrangements (genetic study) 3, 4, 6, 7–8, 10, 11–16
 - medical record checks 11
 - nonflows concept 13, 15–17
 - open access and data sharing policies 17–19
 - organ donation concerns 18–19
 - overflows 17–19
 - overflows, positive test results, significance of 17–18
 - Pakistan samples 13–15, 16–18

- sample collection 10–11, 13, 14–15, 16–17
- sample sharing 120, 128–9
- social scientific study 6–7, 8, 12–14
- trust factors 14–17
- International Covenant on Civil and Political Rights (ICCPR) 74–5, 104–5
- International Covenant on Economic, Social and Cultural Rights (ICESCR) 80, 81, 84
- Ioannidis, J. 131
- Irion, S. 191
- Italy 124–5

- Jafarey, A. 167
- Japan 125–6
- Javaid, M. 125
- Jeffers, B. 216
- Joly, Y. 67, 207, 244, 258, 259
- Jordan, M 242–63
- Jordan, T. 178
- Joskow, P. 200

- Kaiser, J. 176
- Kaitin, K. 201
- Kamuya, D. 169, 170
- Kaufman, D. 182
- Kaye, J. 5, 37, 68, 73, 117–29, 134, 135, 151, 183, 234
- Keating, P. 3
- Keogh, B. 53
- Kere, J. 233
- Kessler, A. 45
- Kinkorová, J. 122
- Kipnis, K. 163, 165–6, 172
- Kirby, E. 135
- Knoppers, B. 258, 259
- knowledge institutions 22–40
 - autonomy protection 36–7
 - Big Data and data science definition 25–6
 - biobanks definition 23–4
 - future challenges 37–9
 - governance definition 26–7
 - knowledge definition 24–5
 - knowledge interests, current and future 27
 - regulatory issues and conflict resolution 26–7
 - resources, complex character of 38–9
 - viability assessment 39
 - see also* information
- knowledge institutions, knowledge commons research framework 27–37
 - commons solutions in new institutional settings, potential for 30
 - governance applications 34–7
 - governance solutions for shared resources subject to social dilemmas 28–31, 32–3
- Institutional Analysis and Development (IAD) framework comparison 30–31, 33
- and intangible information 31
- intellectual property 31–2
- natural resource commons
 - governance comparison 29, 31, 33, 35
- openness and sharing of relevant resources, management of 29–30, 31–2
- ownership interests 36
- personal autonomy, privacy and security issues 36–7
- spillovers from bilateral market transactions 30
- see also* open access

- Kokkat, T. 222
 Kокtvedgaard, M. 113
 Kondylakis, H. 183
 Kongsholm, N. 156–72
 Koskenniemi, M. 256
 Kowal, E. 5–6, 14
 Kreiner, T. 191
 Kroeger, F. 138
 Kulynych, J. 183
- Lander, B. 131
 Landes, W. 200
 Langhof, H. 242, 249, 258
 Lau, B. 178
 Laurie, G. 252
 Laurie, R. 207
 Lauss, G. 15
 Lee, P. 34–5, 36
 legal, ethical, and societal issues (ELSI)
 62–4, 65, 236
 legal framework
 consent problem and uncertainty
 175–6
 Dynamic Consent concept
 120–22, 126–7
 legislation fragmentation,
 developing countries 159
 see also governance structure
 legitimacy requirement for use of
 biosamples 68–9, 70
 Lehtimäki, H. 232
 Lemke, A. 193
 Lemmens, P. 190
 Lemmens, T. 215
 Lemrow, S. 258, 259
 Leonelli, S. 9, 244
 Lévesque, M. 262
 Levin, M. 113
 Levin, N. 244
 Levine, C. 164
 Levy, R. 199
 Lewis, J. 136
- Liddell, K. 51, 52, 54, 242–63
 Liddicoat, J. 51, 52, 54, 242–63
 Lidz, C. 161
 Liede, S. 232
 Light, D. 200
 Lipworth, W. 158
 liquid biopsy tool (plasma sequencing)
 220
 Liu, P. 252
 López, C. 86
 Lou, J. 222
 Luna, F. 163, 164–5
 Luther, L. 215
 Lynch, H. 176
- McCain, K. 205
 McDonald, S. 197
 McGoey, L. 15, 16
 McGuire, A. 175
 Macheiner, T. 218
 Macklin, R. 160
 McLauchlan, C. 212
 Madison, M. 22–40
 Mager, S. 58
 Maggolino, M. 247, 252
 Mallette, A. 256
 Mansfield, E. 199
 Margoni, T. 255, 262
 Marks, J. 6
 Marshall, E. 179
 Mascalzoni, D. 4, 256
 Massett, H. 221
 Master, Z. 120, 174, 176, 177, 193, 196
 Mayrhofer, M. 5, 73, 118, 237
 media hype concern, consent problem
 178–9, 183
 Meijer, I. 5, 197
 Merino-Martinez, R. 54
 Meslin, E. 3
 Meyer, M. 202
 Michalowski, S. 102, 105, 107
 Millien, R. 207

- Minari, J. 126, 127
- Minssen, T. 46, 47, 53, 96, 243
- Mitchell, R. 196, 234
- Moazam, F. 167, 168
- Mol, A. 20
- Möllering, G. 136
- Montagnani, M. 247, 252
- Moodley, K. 130
- morality concerns 12–13, 95, 98, 100, 111, 112–16
see also ethical concerns
- Moran, N. 199
- Moreno, P. 67, 176
- Moufang, R. 100
- Mueller-Langer, F. 209
- Muilu, J. 237
- Mullard, A. 204
- Murdoch, B. 67, 173–84
- Murdoch, C. 189
- Murphy, J. 177
- Murray, K. 179
- Murtagh, M. 191
- Myriad Genetics 42, 51–2, 54
- Nanibaa'A, G. 177
- Nelkin, D. 59
- networks 229–41
 and biomarkers 229, 230, 231, 241
 common ontology requirement 235
 disease-based biobanks 232
 EU BBMRI network, MIABIS (Minimum Information About Biobank Data Sharing) 51, 235, 239
 EU GenomeEUtwin project 237
 genetic association studies 233
 governance structure 239–40
 irreproducibility issues 229
 legal, ethical, and societal issues (ELSI) 236
 'omics' platforms 230, 238
 policy setting role 234, 239
 population-based biobanks 231–2
 research collaborations 234, 235
 sample quantity and quality issues 235–6
 samples and preanalytical variables 230
 social norms and standards, establishment of 234
see also collaboration;
 harmonization approach
- networks, EU BBMRI-ERIC
 infrastructure 118, 157, 202, 236–40
 common services 239–40
 and European research infrastructure (ERA) 237–8
 Expert Centre (EC), academia and industry expertise combination 238–9
 funding commitments and memorandum of understanding (MoU) 238
 interoperability of biobanks and data 237
 quality standards 240
- Nicol, D. 57, 115, 130, 131, 145, 147, 148–9, 154, 180, 194, 196, 197, 214, 243, 247–8, 251, 253, 258, 259
- Nielsen, J. 11
- Nielsen, M. 115
- Nilstun, T. 193, 198
- nonflows concept, and international collaboration 13, 15–17
- Nordberg, A. 96
- Norlin, L. 51, 226, 235
- Nozick, R. 83
- Nys, H. 76, 78

- O'Brien, S. 243
- Odeh, H. 53, 234
- O'Doherty, K. 130
- OECD Guidelines 78–9, 119, 188
- Ogbogu, U. 120, 178, 183
- Olson, J. 191
- 'omics' platforms, networks 230, 238
- Onisto, M. 194
- open access 17–19
- and innovation *see* responsible research and innovation (RRI), open access/open science issues
 - intellectual property policies *see* intellectual property policies for large bioresources, open bioresources, fictional commitment to
 - see also* data sharing; knowledge institutions, knowledge commons research framework
- organ donation concerns 18–19
- Ortega-Paíno, E. 229–41
- Ostrom, E. 28–9, 30, 31, 33, 36, 39
- Overby, C. 130
- Owens, P. 199
- ownership, access and use, Dynamic Consent concept 146–9
- ownership interests, knowledge commons research framework 36
- Pakistan 13–15, 16–18
- blood samples *see* developing countries, exploitation and vulnerabilities in consent to biobank research, Pakistan case study, blood samples
- Pantel, K. 48
- Papoutsis, C. 182
- Park, A. 173, 230
- Parkman, A. 183
- participation consent *see* consent headings
- participation withdrawal rights *see* withdrawal rights
- Pascuzzi, G. 36, 147
- patents
- EU patent law, EU *see* European patent law, free and informed consent in
 - responsible research and innovation (RRI) 189–90, 192–3, 200, 201, 206, 206–8, 209, 212, 213–14
 - rights in international research collaborations 189–90, 200, 201, 206–8
 - see also* intellectual property
- Paterson, G. 112
- Pathmasiri, S. 192, 193, 197, 242, 257, 260
- Patra, P. 10, 14
- Pecci, A. 182
- Peek, N. 44
- Peissl, W. 218
- Penders, B. 6
- Pénin, J. 192
- Perlman, R. 57
- Perren, A. 52
- Perry, M. 147, 259
- Petersen, A. 37, 73, 76
- Petrini, C. 108, 114
- Piciocchi, C. 124
- planned application effects, and expiration dates 223–4
- Plomer, A. 77, 107, 108
- Plotkin, H. 25
- Ploug, T. 134
- Podgurski, A. 44
- population-based biobanks 231–2
- Posner, R. 200
- Poste, G. 229

- poverty and education level effects, developing countries 161
- Prainsack, B. 5
- Pressman, L. 262
- Price, W. 42–55
- Prictor, M 117–29, 134, 135, 151
- privacy concerns 4–5, 13, 30, 36–7, 45, 52–3, 54, 218, 255
and consent problems 121, 128, 181–3
data breaches 181–2
and human rights 74–5, 77, 78–9, 85, 88
see also autonomy;
confidentiality; data sharing
- private biobanks and Guiding Principles on Business and Human Rights 85–6, 88, 89–90
- Proctor, R. 16
- public perception, and consent problem 177–84
- public trust *see* trust factors
- public–private partnerships 87–90, 180–81
- Pullman, D. 192–3, 196
- quality standards 69, 70, 145, 197, 220–23, 225–6, 232–6, 240
see also expiration date for biobanks
- Quinlan, P. 219
- Quinlan, Z. 206
- Rai, A. 54, 244
- Rasmussen, M 2–21
- Reardon, J. 6
- Reardon, S. 176
- regulation fragmentation, Dynamic Consent concept 120–22, 126
- regulatory rule argument, European patent law, free and informed consent in 98–9, 101, 111, 116
- Reichman, J. 35
- residual tissue use, European patent law 108
- Resnik, D. 196
- responsible research and innovation (RRI) 186–215
commercialization effects 193–203, 208, 209–11, 212–14
implementation confusion and conflicts of interest 190–91, 193
industry-sponsored research concerns 194, 198–9
intellectual property
management and patent rights in international research collaborations 189–90, 200, 201, 206–8
patent protection debate 192
societal opposition to new innovations, reducing risk of 188–9
see also human biosamples in bioscience industries, responsible use of; innovation infrastructure for translational medicine
- responsible research and innovation (RRI), open access/open science issues 186–7, 188–9, 203–14
holistic innovation framework 208–14
and intellectual property 206–9
patent donations from industry to research institutions 209, 212
patent rights, use of 209, 213–14
patentability inventive step and novelty 206, 208

- time delays between knowledge and application 204–5, 206, 208
- responsible research and innovation (RRI), stakeholders role in biobanking and medical research 191–203, 210, 211–14
 - collaboration and competing interests 194–5
 - collaborative partnerships
 - between industry and public research organizations 199–200
 - donors' withdrawal rights 197
 - ethical responsibility of
 - researchers to inform donors about potential commercial applications 196–7
 - funding and sustainability 197–8, 212
 - government involvement and socioeconomic growth 202–3
 - public research organization and researchers 201–2
 - public trust issues 195–9, 213–14
 - translational process and contributions required
 - from stakeholders, lack of understanding of 198–9
 - value chains 211–13
- restricted access databases, and intellectual property policies for large bioresources 253
- Rial-Sebbag, E. 255
- Ried, J. 130
- Riegman, P. 59
- risk factors 88, 89, 136–7
- Rochet, J.-C. 139
- Roessner, D. 201, 204
- Rosas, A. 106
- Rose, H. 5
- Rothstein, M. 37
- Rousseau, D. 136, 137
- Ruggie, J. 86
- Ruhleder, K. 9
- Ruse-Khan, H. 256
- St. Laurent, A. 251–2
- sample collection
 - expiration date for biobanks 219–22
 - international collaboration in genetic research 10–11, 13, 14–15, 16–17
 - responsible use *see* human biosamples in bioscience industries, responsible use of
 - storage conditions 69, 74, 220–23, 225–6
 - see also* consent headings
- Sanchini, V. 130
- Sanderson, S. 177
- Sargsyan, K. 216–28
- Schabas, W. 77
- Schatz, U. 100
- Scheltens, P. 46, 132
- Schmalensee, R. 139
- Schmitz, A. 47–8
- Schnackenberg, A. 144
- Schovsbo, J. 46, 47, 53, 92–116
- scientific productions and human rights 73–91
 - autonomy protection 79–80, 88
 - Council of Europe,
 - recommendation on research on biological materials of human origin 79
 - donors' informed consent and withdrawal of consent 75–7
 - European Convention of Human Rights 80–81
 - governance of collections of biological materials 79

- human rights framework 74–80, 81–2
- Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines 87
- International Covenant on Civil and Political Rights (ICCPR) 74–5
- International Covenant on Economic, Social and Cultural Rights (ICESCR) 80, 81, 84
- nondiscrimination and nonstigmatization issues 78
- OECD Guidelines on Human Biobanks and Genetic Research Databases* 78–9
- Oviedo Convention on Human Rights and Biomedicine 75, 77–8, 79, 102–3, 104, 105, 107–8
- privacy rights 74–5, 77, 78–9, 85, 88
- private biobanks and Guiding Principles on Business and Human Rights 85–6, 88, 89–90
- public biobanks 85
- public–private partnership biobanks 87–90
- right to information and donor’s right not to be informed 77–8
- Universal Declaration on the Human Genome and Human Rights 78
- Universal Declaration of Human Rights (UDHR) 74–5, 80, 81, 84
- scientific productions and human rights, intellectual property rights 80–84
- and human rights framework 81–4
- limitation layer 83–4
- moral and material rights 83–4
- WTO TRIPS Agreement 83, 84
- Scotchmer, S. 200
- Scudellari, M. 123
- Seatzu, F. 104
- self-reporting, Dynamic Consent concept 124–5
- Seok, J. 57
- Shabani, M. 258, 259
- Shapiro, C. 203–4
- Sharp, R. 253
- Shaver, L. 77
- Sheller, M. 9, 21
- Sheremeta, L. 211
- Shickle, D. 73
- Shockley, E. 132
- Shore, C. 212
- Silberman, J. 201, 204
- Silvola, S. 110
- Simeon-Dubach, D. 221–2
- Siminoff, L. 182
- Simon, C. 135
- Singh, S. 130
- Skelcher, C. 87
- Skloot, R. 178
- Skopek, J. 252
- Sleeboom-Faulkner, M. 10, 14
- Smith, J. 176
- Soini, S. 184
- Solomon, D. 246
- Somiari, S. and R. 180–81
- Spruessel, A. 222
- stakeholders role in biobanking and medical research *see* responsible research and innovation (RRI), stakeholders role in biobanking and medical research
- Stallman, R. 247
- Star, S. 9

- Steinsbekk, K. 67, 159, 214
- Stephan, P. 205
- Stephens, N. 197, 219
- Sterckx, S. 149
- Stewart, C. 108
- Stilgoe, J. 190
- storage conditions 69, 74, 220–23, 225–6
see also sample collection
- Strandburg, K. 34, 38
- Strange, H. 255
- Stranger, M. 37, 73
- Straus, J. 100
- Strech, D. 118
- Structural Genomics Consortium (SGC)
 247
- Suber, P. 246
- supply chains 58–61, 62–4, 68–9
- sustainability
 Dynamic Consent concept *see*
 Dynamic Consent concept
 and sustainability
 responsible research and
 innovation (RRI) 197–8, 212
- Sweden 97, 98, 104, 109, 113, 231, 232,
 238
- Tamminen, S. 51, 239
- Tassé, A. 118, 135
- Taupitz, J. 130
- Teare, H. 125, 127, 152
- termination costs, expiration date for
 biobanks 218–19, 227
- Terry, S. 174
- Thailand 160
- Thornton, H. 130, 143, 144
- Thorogood, A. 68
- Thursby, M. 209
- time delays between knowledge and
 application, responsible research
 and innovation (RRI) 204–5, 206,
 208
- Timmermans, S. 21
- Tindana, P. 169
- Tirole, J. 139
- Tomlinson, E. 144
- Tomlinson, T. 180
- translational research
 commercialization challenges,
 Dynamic Consent concept
 131–2, 137–8, 148–9
 innovation infrastructure *see*
 innovation infrastructure for
 translational medicine
 responsible research and
 innovation (RRI),
 stakeholders role in
 biobanking and medical
 research 198–9
- transparency, and information evaluation,
 Dynamic Consent concept 143–4,
 149, 152–4
- trials, patients' retroactive involvement
 in 48
- Trinidad, S. 193
- trust factors 14–17, 180–81, 195–9,
 213–14
 and Dynamic Consent *see*
 Dynamic Consent concept and sus-
 tainability, trust challenges
- Tupasela, A. 197, 229–41
- Turner, A. 210–11
- Turney, L. 197
- Tutton, R. 131, 143, 145, 196
- Tyfield, D. 210
- UK 120, 125, 127, 152, 174, 188,
 250–51, 255
- UNESCO International Declaration on
 Human Genetic Data 120, 188
- unforeseen studies, dealing with,
 Dynamic Consent concept
 119–21, 124–5, 126–8
- Universal Declaration on the Human
 Genome and Human Rights 78

- Universal Declaration of Human Rights (UDHR) 74–5, 80, 81, 84
 Urry, J. 9, 21
 US 42, 49, 54, 84, 125, 174, 176, 182, 218
 Alice Corporation v CLS Bank International 260
 Association for Molecular Pathology v Myriad Genetics 260, 261
 Mass. Eye & Ear Infirmary v QLT Phototherapeutics 204, 206
 Mayo Collaborative Services v Prometheus Laboratories 260, 261
 Texas blood samples litigation 184

 value chains, responsible research and innovation (RRI) 211–13
 Van Hoyweghen, I. 183
 Van Looy, B. 201
 Van Ommen, G.-J. 191, 238
 Van Overwalle, G. 35, 99
 Van Zimmeren, E. 130–55
 Varmus, H. 49
 Vaught, J. 173, 234
 Verlinden, M. 53
 Vitullo, M. 77
 Vogl, F. 216–28
 Von Schomberg, R. 188, 190, 203, 215
 Vuorio, E. 118

 Wack, J.-P. 192
 Wagner, J. 175

 Waldby, C. 5, 196, 234
 Walsh, J. 188, 199, 260
 Warburton, R. 200
 Warth, R. 52
 Watson, P. 59, 230
 Wauters, A. 183
 Webster, A. 132
 Wee, R. 128
 Wehling, M. 131
 Weigert, A. 136
 Wendler, D. 160
 Wertheimer, A. 162
 Whipple, W. 53
 Whitley, E. 119, 123, 127, 128
 Wilkinson, M. 50
 Williams, H. 135
 withdrawal rights 75–7, 143, 151, 197
 see also consent headings
 Womack, C. 58
 World Medical Association (WMA) 4, 118, 119
 Wyndham, M. 77

 Yoly, J. 176
 Yu, H. 37, 186–215
 Yu, P. 73–91

 Zaheer, A. 132, 138
 Zaman, R. 167
 Zatloukal, K. 57, 157, 230
 Zawati, M. 68
 Zerhouni, E. 190
 Zheng, Y. 152
 Ziegler, N. 209
 Zika, E. 159, 242, 258, 259